Business Context and Reporting Period
Company: Collegium Pharmaceutical, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 24, 2023
Reporting Period: Specific event date of August 24, 2023.
Key Financial Metrics
This filing is a current report regarding a regulatory event and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change reported is the extension of U.S. market exclusivity for the company's product, Nucynta (tapentadol immediate release). The U.S. Food and Drug Administration (FDA) granted New Patient Population exclusivity, extending the exclusivity period from June 27, 2025, to July 3, 2026.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates a press release announcing the FDA grant. No specific financial guidance or forward-looking revenue projections are included in this document.
Risks and Contingencies: The filing does not explicitly detail new risks or contingencies beyond the standard regulatory context of maintaining exclusivity.
Key Facts for Investor Verification
- Verify the exact new exclusivity end date of July 3, 2026, for Nucynta.
- Confirm the specific "New Patient Population" criteria defined by the FDA for this exclusivity grant.
- Review the attached press release (Exhibit 99.1) for any additional details on the commercial impact of the extension.
- Check subsequent filings for updated financial guidance reflecting the extended exclusivity period.